Tribe Technologies
Trending >

Canadian Bioceutical is still undervalued, says Echelon Wealth Partners

A new partnership for Canadian Bioceutical (CSE:BCC) is being commended by Echelon Wealth Partners analyst Russell Stanley.

This morning, Canadian Bioceutical announced a joint venture with Israeli pharma company Panaxia that will see the pair partner on the sale of products such as sublingual tablets, slow release tablets, rectal suppositories and topical patches.

“Based on the traction Panaxia’s products are enjoying in New Mexico, we believe this joint venture has strong potential to become a material contributor to revenue and margin development,” said Beth Stavola, Canadian Bioceutical’s president of U.S. operations. “Not only will we address a relatively underserved segment of a rapidly growing market, we have no required capital expenditures, making this a very cost-effective way for us to expand product offerings to our patients.”

Stanley notes that this deal allows Canadian Bioceutical to expand its product suite with no Capex requirements.

“Panaxia is to provide the CAPEX to equip BCC’s facilities, including the construction of GMP micro-sites, and will provide the non-active ingredients and compounds for formulation and packaging, with the pre-mix excipients sent from Panaxia’s GMP production facility in Israel,” the analyst explains. “The resulting revenue is to be shared 50/50.”

In a research update to clients today, Stanley maintained his “Speculative Buy” rating and one-year price target of $0.65 on Canadian Bioceutical, implying a return of 76 per cent at the time of publication.

Stanley thinks Canadian Bioceutical will generate EBITDA of $4.8-million on revenue of $29.4-million in fiscal 2018. He expects those numbers will improve to EBITDA of $11.9-million on a topline of $47.9-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook


Leave a Reply